Europe Approves Regeneron - Roche's COVID-19 Antibody Cocktail - Roche Holding (OTC:RHHBF), Roche Holding (OTC:RHHVF), Regeneron Pharmaceuticals (NASDAQ:REGN), Roche Holding (OTC:RHHBY)

The European Commission (EC) has approved Regeneron Pharmaceuticals Inc's REGN COVID-19 antibody cocktail, known as REGEN-COV in the U.S. and Ronapreve in the European Union (EU) and other countries.
The authorization comes for people aged 12 years and older to treat non-hospitalized patients (outpatients) with confirmed COVID-19 who do not require oxygen supplementation and who are at increased risk of progressing to severe COVID-19 and to prevent COVID-19.
Related Link: EU Regulator Backs Regeneron-Roche's COVID-19 Drug.
In October, the FDA accepted for priority review the first of two marketing applications for REGEN-COV to treat COVID-19 in non-hospitalized patients and as prophylaxis in certain individuals.
The second application will focus on those hospitalized because of COVID-19 and is expected to be completed later this year.
Regeneron is collaborating with Roche Holdings AG RHHBY for the antibody cocktail.
Price Action: REGN shares are up 0.32% at $628.62, RHHBY shares are down 0.54% at $50.11 during the market session on the last check Friday.